Lahita's Systemic Lupus Erythematosus
- 6th Edition - July 23, 2021
- Latest edition
- Editor: Robert Lahita
- Language: English
Lahita's Systemic Lupus Erythematosus, Seventh Edition is a current, authoritative reference on systemic lupus erythematosus (SLE), one of the most heterogeneous and mechan… Read more
End of Summer Sale
Save up to 30% off
Bright savings for research, study, and discovery
Description
Description
The reference spans the full breadth of SLE biology and clinical management. Content covers the genetic and epigenetic determinants of susceptibility, B and T cell dysregulation, innate immune mechanisms including interferon signaling and neutrophil biology, complement activation, microbiome contributions, and metabolic dysfunction in immune cells. Clinical content addresses the presentation and management of SLE across organ systems—including renal, neuropsychiatric, cardiovascular, pulmonary, cutaneous, musculoskeletal, and hematologic manifestations—alongside antiphospholipid syndrome and malignancy surveillance. Therapeutic chapters span antimalarials and glucocorticoids through approved targeted biologics and investigational CAR-T cell approaches, with attention to pregnancy management, global health disparities, and precision treatment strategies.
Lahita's Systemic Lupus Erythematosus equips rheumatologists, clinical immunologists, and multidisciplinary specialists with the scientific foundation and clinical guidance required for contemporary SLE practice. Contributions from international experts spanning five continents provide a global perspective on disease heterogeneity and outcomes. Integrated coverage of AI-assisted monitoring, molecular biomarkers, and precision stratification frameworks positions this reference as essential reading for clinicians and translational researchers in autoimmunity.
Key features
Key features
• Covers approved and investigational therapies including type I interferon blockade and CAR-T cell approaches
• Addresses precision medicine frameworks incorporating AI-driven monitoring and molecular patient stratification
• Provides international perspectives on SLE epidemiology, health disparities, and outcomes
Readership
Readership
Table of contents
Table of contents
Part I: Basis of the Disease
Section A: Genetics and epigenetics
1. Major histocompatibility complex and SLE
2. Lupus Susceptibility genes
3. Epigenetics in systemic lupus erythematosus and the integration of molecular pathways
Section B: Immunopathogenesis
4. Autoantigens, antigenic mimicry, and immune complexes
5. B-cell Biology, tolerance and autoantibodies
6. T-Cell Biology, tolerance and regulation
7. Polymorphonuclear cells
8. Metabolic and mitochondrial dysfunction in SLE
9. Immunopathogenesis: the role of mucosal and skin microbiota in SLE
Section C: Disease effectors and modifiers
10. Complement and SLE
11. Interferons and cytokines in SLE pathogenesis and therapy
12. Innate immunity in SLE pathogenesis
13. Sex bias in SLE
Section D: Tissue injury—the Biology
14. Mechanisms of tissue injury in lupus nephritis
15. The skin
16. The brain in SLE: mechanisms and detection of injury and therapeutic strategies
17. The role of infections in SLE pathogenesis
18. Tissue injurydthe biology: SLE-associated vascular disease and antiphospholipid syndrome
Part II: Clinical presentation of disease
Section A: Clinical presentation
19. Epidemiology of SLE and related diseases: incidence, prevalence, and mortality
20. The clinical presentation of systemic lupus erythematosus and laboratory diagnosis
21. Passively acquired lupus in the fetus and neonate
22. Systemic lupus erythematosus in children
23. Environmental and drug-induced lupus
24. Reproductive health
25. Monitoring disease activity
26. Overlap syndromes
Section B: Specific organ involvement and clinical presentation
27. Nervous system
28. Skin
29. Kidney disease
30. Cardiovascular disease in lupus
31. Pulmonary manifestations of systemic lupus erythematosus
32. GI hepatic and nonhepatic diseases
33. Musculoskeletal system: articular disease, myositis, and bone metabolism
34. Clinical presentation of antiphospholipid syndrome
35. Hematology: cytopenias
36. Malignancy risk and screening
Section C: Treatment of systemic llupus erythematosus
37. Antimalarial drugs (and lupus)
38. Glucocorticoids
39. Immunosuppressive therapy in SLE
40. Pipeline therapies and future drug development
41. Challenges of systemic lupus clinical trials
Review quotes
Review quotes
Product details
Product details
- Edition: 6
- Latest edition
- Published: July 27, 2021
- Language: English
About the editor
About the editor
RL
Robert Lahita
Robert G. Lahita, MD, PhD, is Clinical Professor of Medicine at Hackensack Meridian School of Medicine and Director of the Institute for Autoimmune and Rheumatic Diseases at St. Joseph's Health, Wayne, New Jersey. A Fellow of the American College of Physicians and the Royal College of Physicians, and a Master of the American College of Rheumatology, he serves as Associate Editor of Lupus: An International Journal. His research focuses on the immunopathogenesis of systemic lupus erythematosus, immune endocrinology, and the hormonal regulation of autoimmunity. He has served as editor of Systemic Lupus Erythematosus across multiple editions and as Senior Editor of the Textbook of Autoimmune Diseases.